Drug
Txn10128
Txn10128: highest development phase Phase 1/2, developed by Txinno Bioscience Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Txinno Bioscience Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| TXN10128 NCT07933055 | Phase 1/2 | NSCLC (Non-small Cell Lung Cancer) |
Latest
No recent events.
Follow Txn10128 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.